Vitruvias Therapeutics has issued a nationwide recall for one lot of its Thyroid Tablets, USP 30 mg, identified as Lot No. 504950, due to confirmed potential for super potency. This recall addresses a significant health risk, as superpotent thyroid medication can lead to hyperthyroidism.
Consumption of these superpotent tablets may cause symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. The elderly, pregnant women, and infants are particularly vulnerable to adverse outcomes, including cardiac issues in the elderly and developmental problems in infants.
The affected Lot 504950 was distributed across the USA to direct accounts between January 31, 2025, and September 30, 2025. Despite the potential risks, Vitruvias Therapeutics has not yet received any reports of adverse events directly linked to this specific recall.
Consumers currently using Thyroid, USP from the recalled lot should consult their physician or healthcare provider immediately for guidance and a replacement prescription, and should not discontinue use without medical advice. Adverse events can be reported to the FDA's MedWatch program.